Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.51 USD
Change Today -0.22 / -12.72%
Volume 2.9M
VVUS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

vivus inc (VVUS) Snapshot

Open
$1.69
Previous Close
$1.73
Day High
$1.69
Day Low
$1.28
52 Week High
09/18/14 - $4.82
52 Week Low
07/31/15 - $1.28
Market Cap
156.8M
Average Volume 10 Days
1.5M
EPS TTM
$-0.74
Shares Outstanding
103.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VIVUS INC (VVUS)

vivus inc (VVUS) Related Businessweek News

View More BusinessWeek News

vivus inc (VVUS) Details

VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension. The company has development, license and clinical trial, and commercial supply agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. It also has license and commercialization agreements with Berlin-Chemie AG and Auxilium Pharmaceuticals, Inc. to commercialize and promote SPEDRA; and with Sanofi Winthrop Industrie to commercialize and promote avanafil. VIVUS, Inc. was founded in 1991 and is headquartered in Mountain View, California.

94 Employees
Last Reported Date: 02/25/15
Founded in 1991

vivus inc (VVUS) Top Compensated Officers

Chief Executive Officer, Chief Commercial Off...
Total Annual Compensation: $650.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $350.0K
Senior Vice President of Business Development...
Total Annual Compensation: $425.0K
Vice President of Clinical Development
Total Annual Compensation: $432.3K
Vice President of Medical & Regulatory Affair...
Total Annual Compensation: $385.0K
Compensation as of Fiscal Year 2014.

vivus inc (VVUS) Key Developments

VIVUS Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

VIVUS Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net loss of $49.35 million or $0.48 per basic and diluted share on total revenue of $23 million compared to net loss of $25.8 million or $0.25 per basic and diluted share on total revenue of $21.9 million reported in the same period last year. Loss from operations was $41.2 million against $17.5 million reported last year. Loss before income taxes was $49.3 million against $25.8 million reported last year. Net loss, excluding inventory impairment charges of $29.5 million, was $19.8 million, or $0.19 net loss per share, in the current quarter, compared to a net loss of $25.8 million, or $0.25 net loss per share, in the second quarter of 2014. For the six months, the company reported net loss of $64.8 million or $0.62 per basic and diluted share on total revenue of $55.15 million compared to net loss of $41.4 million or $0.40 per basic and diluted share on total revenue of $58.6 million reported in the same period last year. Loss from operations was $48.0 million against $25.4 million reported last year. Loss before income taxes was $64.8 million against $41.8 million reported last year.

VIVUS Inc. to Report Q2, 2015 Results on Jul 30, 2015

VIVUS Inc. announced that they will report Q2, 2015 results at 4:30 PM, US Eastern Standard Time on Jul 30, 2015

VIVUS Inc., Q2 2015 Earnings Call, Jul 30, 2015

VIVUS Inc., Q2 2015 Earnings Call, Jul 30, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VVUS:US $1.51 USD -0.22

VVUS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $4.04 USD +0.07
GlaxoSmithKline Consumer Healthcare Ltd 6,294 INR 0.00
Novo Nordisk A/S kr398.40 DKK +1.20
Orexigen Therapeutics Inc $4.00 USD +0.05
Takeda Pharmaceutical Co Ltd ¥6,240 JPY +138.00
View Industry Companies
 

Industry Analysis

VVUS

Industry Average

Valuation VVUS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.4x
Price/Book 7.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VIVUS INC, please visit www.vivus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.